TY - JOUR
T1 - Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides
T2 - Results of a pooled analysis from 3 phase-II clinical trials
AU - Hoppe, Richard T.
AU - Harrison, Cameron
AU - Tavallaee, Mahkam
AU - Bashey, Sameer
AU - Sundram, Uma
AU - Li, Shufeng
AU - Million, Lynn
AU - Dabaja, Bouthaina
AU - Gangar, Pamela
AU - Duvic, Madeleine
AU - Kim, Youn H.
N1 - Publisher Copyright:
© 2014 by the American Academy of Dermatology, Inc.
PY - 2015
Y1 - 2015
N2 - Background: Standard-dose (36-Gy) total skin electron beam therapy (TSEBT) is a highly effective treatment in mycosis fungoides. However, the regimen is time-intensive and may be associated with significant toxicity. Objective: We sought to evaluate the efficacy and tolerability associated with low-dose (12-Gy) TSEBT. Methods: Data from 3 clinical trials using low-dose (12-Gy) TSEBT were pooled. In all trials, TSEBT-naïve patients with stage IB to IIIA mycosis fungoides were treated with TSEBT (12 Gy, 1 Gy per fraction over 3 weeks). The primary end point was clinical response rate. Secondary end points included time to response and duration of clinical benefit. Results: In all, 33 patients enrolled. Eighteen were male; stages were 22 IB, 2 IIA, 7 IIB, and 2 IIIA. Overall response rate was 88% (29/33), including 9 patients with complete response. Median time to response was 7.6 weeks (3-12.4 weeks). Median duration of clinical benefit was 70.7 weeks (95% confidence interval 41.8-133.8 weeks). Toxicities from TSEBT were mild and reversible. Limitations: Conclusions are limited because of the small number of patients. Conclusions: Low-dose TSEBT provides reliable and rapid reduction of disease burden in patients with mycosis fungoides, which could be administered safely multiple times during the course of a patient's disease with acceptable toxicity profile.
AB - Background: Standard-dose (36-Gy) total skin electron beam therapy (TSEBT) is a highly effective treatment in mycosis fungoides. However, the regimen is time-intensive and may be associated with significant toxicity. Objective: We sought to evaluate the efficacy and tolerability associated with low-dose (12-Gy) TSEBT. Methods: Data from 3 clinical trials using low-dose (12-Gy) TSEBT were pooled. In all trials, TSEBT-naïve patients with stage IB to IIIA mycosis fungoides were treated with TSEBT (12 Gy, 1 Gy per fraction over 3 weeks). The primary end point was clinical response rate. Secondary end points included time to response and duration of clinical benefit. Results: In all, 33 patients enrolled. Eighteen were male; stages were 22 IB, 2 IIA, 7 IIB, and 2 IIIA. Overall response rate was 88% (29/33), including 9 patients with complete response. Median time to response was 7.6 weeks (3-12.4 weeks). Median duration of clinical benefit was 70.7 weeks (95% confidence interval 41.8-133.8 weeks). Toxicities from TSEBT were mild and reversible. Limitations: Conclusions are limited because of the small number of patients. Conclusions: Low-dose TSEBT provides reliable and rapid reduction of disease burden in patients with mycosis fungoides, which could be administered safely multiple times during the course of a patient's disease with acceptable toxicity profile.
KW - Cutaneous lymphoma
KW - Low-dose total skin electron beam therapy
KW - Radiotherapy
KW - T-cell lymphoma
KW - Total skin electron beam therapy
UR - http://www.scopus.com/inward/record.url?scp=84922567743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922567743&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2014.10.014
DO - 10.1016/j.jaad.2014.10.014
M3 - Article
C2 - 25476993
AN - SCOPUS:84922567743
SN - 0190-9622
VL - 72
SP - 286
EP - 292
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -